Top Core and Group Health Stories
New bipartisan bill targets drug prices--and Mylan
By Marlene SatterThe bill would allow HHS to reclassify a drug and recoup rebates when a manufacturer deliberately misclassifies a drug.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
The bill would allow HHS to reclassify a drug and recoup rebates when a manufacturer deliberately misclassifies a drug.